Literature DB >> 26646047

Residual symptoms in depression: prevalence and impact.

Andrew A Nierenberg1.   

Abstract

Residual symptoms are experienced by most patients being treated for depression, including those who have achieved remission. These symptoms prevent individuals from fully recovering and feeling truly "well." Often, symptoms that are related to deficits in positive affect (such as anhedonia, pessimism, and lack of motivation) persist after the other symptoms of depression (such as irritability, distress, and low mood) have resolved. Clinicians must assess patients for residual symptoms using rating scales (eg, the Patient Health Questionnaire, Clinical Positive Affect Scale) and adjust treatment to improve patients' sense of well-being and normalcy. © Copyright 2015 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Year:  2015        PMID: 26646047     DOI: 10.4088/JCP.13097TX1C

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  12 in total

Review 1.  Inflammation Effects on Motivation and Motor Activity: Role of Dopamine.

Authors:  Jennifer C Felger; Michael T Treadway
Journal:  Neuropsychopharmacology       Date:  2016-08-02       Impact factor: 7.853

Review 2.  Anhedonia in depression and schizophrenia: A transdiagnostic challenge.

Authors:  Clare Lambert; Susana Da Silva; Amanda K Ceniti; Sakina J Rizvi; George Foussias; Sidney H Kennedy
Journal:  CNS Neurosci Ther       Date:  2018-04-23       Impact factor: 5.243

3.  Reward-Related Neural Predictors and Mechanisms of Symptom Change in Cognitive Behavioral Therapy for Depressed Adolescent Girls.

Authors:  Christian A Webb; Randy P Auerbach; Erin Bondy; Colin H Stanton; Lindsay Appleman; Diego A Pizzagalli
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2020-07-23

4.  The Increasing Economic Burden with Additional Steps of Pharmacotherapy in Major Depressive Disorder.

Authors:  Alix Arnaud; Ellison Suthoff; Rita M Tavares; Xuan Zhang; Aditi J Ravindranath
Journal:  Pharmacoeconomics       Date:  2021-04-28       Impact factor: 4.981

5.  An observational study of duloxetine versus SSRI monotherapy in Japanese patients with major depressive disorder: subgroup analyses of treatment effectiveness for pain, depressive symptoms, and quality of life.

Authors:  Atsushi Kuga; Toshinaga Tsuji; Shinji Hayashi; Shinji Fujikoshi; Hirofumi Tokuoka; Aki Yoshikawa; Rodrigo Escobar; Kazuhide Tanaka; Takaharu Azekawa
Journal:  Neuropsychiatr Dis Treat       Date:  2017-08-04       Impact factor: 2.570

Review 6.  Imaging the Role of Inflammation in Mood and Anxiety-related Disorders.

Authors:  Jennifer C Felger
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

7.  The neuroprogressive nature of major depressive disorder: evidence from an intrinsic connectome analysis.

Authors:  Jin Liu; Yiming Fan; Bangshan Liu; Yumeng Ju; Mi Wang; Qiangli Dong; Xiaowen Lu; Jinrong Sun; Liang Zhang; Hua Guo; Li Zhang; Zexuan Li; Mei Liao; Yan Zhang; Dewen Hu; Lingjiang Li
Journal:  Transl Psychiatry       Date:  2021-02-04       Impact factor: 6.222

8.  Efficacy of Vortioxetine on Anhedonia: Results from a Pooled Analysis of Short-Term Studies in Patients with Major Depressive Disorder.

Authors:  Roger S McIntyre; Henrik Loft; Michael Cronquist Christensen
Journal:  Neuropsychiatr Dis Treat       Date:  2021-02-22       Impact factor: 2.570

9.  Patient Expectations and Experiences of Antidepressant Therapy for Major Depressive Disorder: A Qualitative Study.

Authors:  Bernhard T Baune; Ioana Florea; Bjarke Ebert; Maëlys Touya; Anders Ettrup; Monica Hadi; Hongye Ren
Journal:  Neuropsychiatr Dis Treat       Date:  2021-09-23       Impact factor: 2.570

10.  Profiles of Recovery from Mood and Anxiety Disorders: A Person-Centered Exploration of People's Engagement in Self-Management.

Authors:  Simon Coulombe; Stephanie Radziszewski; Sophie Meunier; Hélène Provencher; Catherine Hudon; Pasquale Roberge; Martin D Provencher; Janie Houle
Journal:  Front Psychol       Date:  2016-04-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.